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ABSTRACT
Objective To determine the effect of sex on the risk of
recurrent venous thromboembolism in all patients and in
patients with venous thromboembolism that was
unprovoked or provoked (by non-hormonal factors).
Data source Comprehensive search of electronic
databases (Medline, Embase, CINAHL, Cochrane Central
Register of Controlled Trials) until July 2010,
supplemented by review of conference abstracts and
contact with content experts.
Study selection Seven prospective studies investigating
an association between D-dimer, measured after
anticoagulation was stopped, and disease recurrence in
patients with venous thromboembolism.
Data extraction Patient level databases were obtained,
transferred to a central database, checked, and
completed with further information provided by authors.
Data synthesis 2554 patients with a first venous
thromboembolism had follow-up for a mean of 27.1 (SD
19.6) months. The one year incidence of recurrent venous
thromboembolism was 5.3% (95% confidence interval
4.1% to 6.7%) in women and 9.5% (7.9% to 11.4%) in
men, and the three year incidence of recurrencewas 9.1%
(7.3% to 11.3%) in women and 19.7% (16.5% to 23.4%)
in men. Among patients with unprovoked venous
thromboembolism, men had a higher risk of recurrence
than did women (hazard ratio 2.2, 95% confidence
interval 1.7 to 2.8). After adjustment for women with
hormone associated initial venous thromboembolism,
the risk of recurrence remained higher in men (hazard
ratio 1.8, 1.4 to 2.5). In patients with provoked venous
thromboembolism, occurring after exposure to a major
risk factor, recurrence of disease did not differ between
men and women (hazard ratio 1.2, 0.6 to 2.4). In women
with hormone associated venous thromboembolism and
no other risk factors, recurrence was lower than that in
women with unprovoked venous thromboembolism and
no previous hormone use (hazard ratio 0.5, 0.3 to 0.8).
Conclusion In patients with a first unprovoked venous
thromboembolism, men have a 2.2-fold higher risk of
recurrent venous thromboembolism than do women,
which remained 1.8-fold higher in men after adjustment
for previous hormone associated venous
thromboembolism in women. In patients with a first
provoked venous thromboembolism, risk of recurrence
does not differ between men and women with or without
hormone associated venous thromboembolism.
Indefinite anticoagulation may be given greater
consideration in men than in women after a first venous
thromboembolism.
INTRODUCTION
Men andwomen are at similar risk of developing a first
episode of venous thromboembolism,1-3 butmen seem
to have a 1.5-fold to 2.5-fold higher risk of recurrent
venous thromboembolism after anticoagulant treat-
ment is stopped.4-6 In all patients (men and women)
with unprovoked venous thromboembolism, who
comprise about a half of all patients with venous
thromboembolism,78 the five year risk of recurrence
is 20-30%.89 If the risk is truly 1.5-fold to 2.5-fold
higher in men than in women, this may warrant con-
sideration of indefinite (which may be lifelong) anti-
coagulation in men with unprovoked venous
thromboembolism.
The putative association between male sex and
increased risk of recurrent venous thromboembolism
has not been seen in large, community based epide-
miological studies,9 10 and it may be attributable to
two potential confounders. The first is patient’s age.
Inmost studies that compared risk of recurrent disease
in men and women, men were older,11 and increasing
age may be a risk factor for recurrent venous throm-
boembolism as it is with initial disease.12 13 The second
is the inclusion of women with hormone associated
initial venous thromboembolism, defined as venous
thromboembolism that occurs during exposure to
oral contraceptive or hormone replacement therapy
and no exposure to other risk factors for venous throm-
boembolism. As women with hormone associated
venous thromboembolism are thought to have a low
risk of recurrent disease, because hormonal therapy is
a reversible risk factor for venous thromboembolism,14
the increased risk in men may be spurious and attribu-
table to a lower risk in women.15
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A study level meta-analysis found a 1.6-fold higher
risk of recurrent venous thromboembolism in men
than inwomen but could not adjust for potentially con-
founding variables such as patient’s age and hormone
associated venous thromboembolism.11 The uncer-
tainty about the importance of sex as a risk factor for
recurrent venous thromboembolism has prompted
calls for further study.16 One way to overcome this
uncertainty is with patient level meta-analysis, which,
unlike study level meta-analysis, can adjust for poten-
tially confounding variables.17
We did a meta-analysis of data from individual
patients derived fromprospective studies that included
patients with a first venous thromboembolism who
received standardised anticoagulant treatment, had
post-anticoagulation D-dimer testing, and were fol-
lowed for recurrence of disease after treatment was
stopped. Our primary aim was to determine the inde-
pendent effect of sex on the risk of recurrent venous
thromboembolism in all patients and in patients with
venous thromboembolism that was unprovoked or
provoked (by non-hormonal factors). Secondarily, we
aimed to determine if womenwith hormone associated
initial venous thromboembolism were, as postulated,
at lower risk for recurrence than were women who
developed venous thromboembolism without pre-
vious exposure to hormonal therapy.
METHODS
A core group of investigators (JD, AT, and AI) devel-
oped the process for obtaining patient level data and
the planned analyses, and all the co-authors approved
thembefore the data collection phase.Ourmain objec-
tive was to develop a clinical prediction guide
anchored on post-anticoagulation D-dimer status to
distinguish patients’ risk of recurrent venous throm-
boembolism, which has been published elsewhere.18
However, the richness of this database provided an
opportunity to answer additional clinical questions
relevant to general physicians, one of which is the
focus of the study reported here.
Study selection
For selection of studies, we adopted the search strategy
used for a previous study level meta-analysis,19 updat-
ing it to include more recent studies (web appendix 1).
We searched major electronic databases (Medline,
Embase, CINAHL, Cochrane Central Register of
Controlled Trials) from their inception to July 2010.
Source study characteristics
Included studies had the following characteristics: ran-
domised trial or prospective cohort study of patients
with a first symptomatic venous thromboembolism;
patients received anticoagulation with five to 10 days
of heparin and at least three months of a vitamin K
antagonist; patients had follow-up for recurrent symp-
tomatic venous thromboembolism after anti-
coagulation was stopped, with outcomes objectively
confirmed and independently adjudicated; and D-
dimer was measured after anticoagulation was
stopped. This last characteristic was not needed for
the analysis reported here but was used for companion
studies.18 20 Patients were excluded from the source stu-
dies if they had at least one of the followingwhen initial
venous thromboembolismwas diagnosed: cancer, per-
manent immobility, antiphospholipid antibodies, and
antithrombin deficiency.
Source study quality assessment
As standardised quality criteria for meta-analyses of
prognostic studies are lacking,21 22 we used a modified
Newcastle-Ottawa scale score to assesses the quality of
non-randomised studies.23We evaluated the studies on
the basis of the selection and outcome criteria alone, as
the availability of patient level data renders selection
criteria irrelevant. A study was high quality if the score
was 4 or over.24 We planned to include the Newcastle-
Ottawa scale score as a covariate in the regression ana-
lysis to evaluate its possible effect on outcome effects.
Patient population
The study population comprised patients who had all
stopped anticoagulant treatment, irrespective of post-
anticoagulation D-dimer status. For two included stu-
dies (randomised trials) that allocated some patients
with a positive D-dimer to resume anti-coagulation,2526
we excluded such patients from our analyses. To char-
acterise subgroups of patients pertinent to our analyses,
we pre-specified the following definitions and applied
them to all study populations.
Unprovoked venous thromboembolism—Venous throm-
boembolism that occurred in the absence of an antece-
dent major clinical risk factor: surgery, trauma, active
cancer, immobility, or pregnancy and the puerperium.
We also classified venous thromboembolism that
occurred in association with hormonal therapy (oral
contraceptive or hormone replacement therapy) or a
thrombophilic blood abnormality and no other risk
factors for venous thromboembolism as unprovoked.
This was justified because hormonal therapy is consid-
ered aweak risk factor for venous thromboembolism,14
and because thrombophilic abnormalities, although
they increase the risk of initial venous thromboembo-
lism, do not seem to increase the risk of recurrent
disease.27
Provoked venous thromboembolism—Venous throm-
boembolism that occurred in the presence of an ante-
cedent and transient major clinical risk factor for
venous thromboembolism (as mentioned above) that
occurred within three months of the initial venous
thromboembolism, irrespective of exposure to conco-
mitant hormonal therapy or the presence of a throm-
bophilia.We considered pregnancy associated venous
thromboembolism to be provoked because the left
sided predominance of lower limb venous thrombosis
suggests a transient, stasis related pathogenesis.28 We
considered postpartum venous thromboembolism to
be provoked, as it is similar in pathogenesis to surgery
associated venous thromboembolism.14
Hormone associated venous thromboembolism—Venous
thromboembolism that occurred in women who were
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receiving hormonal therapy (oral contraceptive or hor-
mone replacement therapy) at the time of the initial
venous thromboembolism and who had no additional
risk factors. In our primary analysis, we combined oral
contraception and hormone replacement therapy as a
single risk factor because both types of oral hormonal
therapy confer a similar twofold to fourfold increased
risk for venous thromboembolism.29 30 In our study, all
users of hormonal therapy had received an oral contra-
ceptive or oral hormone replacement therapy, and our
findings do not pertain to users of non-oral forms of
hormonal therapy.
Patient follow-up and outcomes
Follow-up started when anticoagulant treatment was
stopped and ended when one of the following
occurred: the patient developed recurrent venous
thromboembolism with symptoms, the patient died
from another cause, anticoagulation was restarted for
another reason, or the study ended. No patient
resumed anticoagulation during follow-up unless
recurrent venous thromboembolism occurred or the
patient developed another clinical indication for anti-
coagulant treatment.
Statistical analyses
We used Kaplan-Meier analysis to calculate the
cumulative incidence of recurrent venous thromboem-
bolism, with associated 95% confidence intervals, at
one, three, and five years after anticoagulation was
stopped. We did this for all men, all women, men
with unprovoked venous thromboembolism, women
with unprovoked venous thromboembolism (includ-
ing and excluding women with hormone associated
disease), and women with hormone associated venous
thromboembolism.
We calculated hazard ratios and 95% confidence
intervals for recurrent venous thromboembolism in
men compared with women by using multivariable
Cox regression (without and with adjustment for hor-
mone associated initial venous thromboembolism
occurring in women). We allowed for across study het-
erogeneity by initially running a Cox model with ran-
dom effect (“shared frailty” γ distributed) for the study
variable. If we found no significant variance of γ distri-
bution, we used a study stratified Cox model under the
fixed effect assumption. Other variables in the regres-
sion model were patient’s age, cause of venous throm-
boembolism (unprovoked or provoked), interaction
between cause of venous thromboembolism and
patient’s sex, and extent of deep vein thrombosis (prox-
imal or distal).Wehandled patient’s age as a continuous
variable and an on-average centred variable calculated
for each patient by subtracting the mean age of the
entire study population from the patient’s age.
We retained all variables if P was less than 0.10 or if
they significantly affected the regression coefficients of
other variables. We calculated hazard ratios for recur-
rent venous thromboembolism in men versus women
with either unprovoked or provoked venous throm-
boembolism (we repeated these analyses after
adjustment for women with hormone associated initial
venous thromboembolism).We also calculated hazard
ratios in women with hormone associated venous
thromboembolism versus women without any antece-
dent risk factors.We assessed the proportional hazards
assumption by analysis of Schoenfeld residuals.
Sensitivity analyses
To investigate more extensively the effect of patient’s
age and hormone associated initial venous throm-
boembolism (in women) on the risk of recurrence in
men and women, coupled with our premise that these
factorsmight be reciprocal confounders,11-14 16 we did a
post hoc sensitivity analysis with two aims: to investi-
gate if the effect of patient’s sex and hormone asso-
ciated initial venous thromboembolism on risk of
recurrence was age specific and to assess if use of oral
contraceptive versus hormone replacement therapy
during the initial venous thromboembolism had a
role in determining the risk of recurrence. We
achieved the first aim by adding the interaction terms
between age and sex and between age and hormonal
therapy in the multivariable Cox model. We inserted
patient’s age first as a continuous variable and also as a
dichotomised variable (≥60 or <60 years, based on the
mean and median age of the study population). We
achieved the second aim by fitting only women in a
multivariable Cox model with a three level variable,
categorising women as oral contraceptive users, hor-
mone replacement therapy users, or non-hormone
users.
RESULTS
Source study and patient characteristics
Web appendices 1 and 2 show the derivation of the
source studies used in this meta-analysis,25 26 31-35 and
table 1 describes their characteristics. Table 2
describes the characteristics of the study population
of 2554 patients with a first venous thromboembolism
with symptoms. The mean length of follow-up was
27.1 (SD 19.6) months, and the median length of fol-
low-up was 22.3 (range 0.2-117.3) months. One hun-
dred and ninety-three recurrences of venous
thromboembolismoccurred inmenduring 36 046per-
son years of follow-up, and 97 recurrences occurred in
women during 33 182 person years of follow-up.
Source study quality assessment
All included studies were of high quality according to
the Newcastle-Ottawa scale (table 1), and an analysis
evaluating the effect of differences in study quality was
not needed.
Cumulative incidence of recurrent venous
thromboembolism
Table 3 shows the cumulative incidence of recurrent
venous thromboembolism according to subgroups of
patients definedbypatient’s sex and cause (unprovoked
or provoked) of the initial venous thromboembolism.
The one year incidence of recurrent venous
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thromboembolism was 5.3% (95% confidence interval
4.1% to 6.7%) in women and 9.5% (7.9% to 11.4%) in
men; the three year incidence of recurrence was 9.1%
(7.3% to 11.3%) in women and 19.7% (16.5% to 23.4%)
in men. Venous thromboembolism recurred less fre-
quently in women than in men at any time during fol-
low-up, irrespective of the subgroup studied.
Risk factors for recurrent venous thromboembolism
Table 4 shows the hazard ratios for predictors of recur-
rent venous thromboembolism. The log hazard ratio
function was constant over time for the entire model.
When we did variable by variable tests, the propor-
tional hazard assumption was valid for all variables
except for the extent of venous thrombosis variable.
Including this variable in the model or excluding it
from themodel did not affect the other Cox regression
coefficients.
Men and women with unprovoked venous thromboembo-
lism—When we compared men and women with
unprovoked venous thromboembolism (including
womenwith hormone associated initial venous throm-
boembolism but no other risk factors), men had a 2.2-
fold higher risk of recurrent disease than did women
(hazard ratio 2.2, 95% confidence interval 1.7 to 2.8).
When we repeated this comparison after adjustment
for women with hormone associated venous throm-
boembolism, the risk of recurrence remained 1.8-fold
higher in men with unprovoked venous thromboem-
bolism than in women with unprovoked venous
thromboembolism (hazard ratio 1.8, 1.4 to 2.5). In
addition, when we adjusted for use of hormonal ther-
apy (at the time of the initial venous thromboembo-
lism), patient’s age was no longer an independent
predictor of recurrence (unadjusted hazard ratio 1.01,
1.00 to 1.02, P=0.030; adjusted hazard ratio 1.00, 0.99
to 1.01, P = 0.29).
Men and women with provoked venous thromboembolism
—Whenwe comparedmenandwomenwith provoked
venous thromboembolism,we foundno significant dif-
ference in risk of recurrence betweenmen and women
(hazard ratio 1.2, 0.6 to 2.4). When we repeated this
comparison after adjusting for women who had
concomitant exposure to hormonal therapy, the lack
of difference in risk of recurrence of venous throm-
boembolism between men and women persisted
(hazard ratio 1.2, 0.6 to 2.3).
Women with or without hormone associated initial venous
thromboembolism—In an analysis limited towomenwith
venous thromboembolism who had no major risk fac-
tors before their initial venous thromboembolism,
those whose disease occurred in association with hor-
monal therapy had a 50% lower risk of recurrence than
did women without hormone associated venous
thromboembolism (hazard ratio 0.5, 0.3 to 0.8).
Table 1 | Characteristics of source studies
Author, year Study design Inclusion (exclusion) criteria Index VTE Monitoring for recurrent VTE
Study quality assessment
according to modified NOS
criteria (selection/outcome)*
Palareti, 200331 Prospective cohort,
single centre
First VTE (excluded: lupus anticoagulant) Leg DVT or PE Clinical visits 3 months after
stopping vitamin K antagonist, then
every 6 months; instructions to
contact if have symptoms
4/3
Eichinger, 200332 Prospective cohort,
single centre
First unprovoked VTE (excluded: surgery, trauma, or
pregnancy within previous 3 months; cancer; APS;
natural coagulation inhibitor deficiency; long term
anticoagulation)
Leg DVT or PE Clinical visits every 3 months for
1 year, then every 6 months
3/3
Palareti, 200626 Randomised
controlled,
multicentre
First unprovokedVTE (excluded: recent pregnancy or
puerperium, fracture or plaster casting of leg,
immobilisation for≥3consecutivedays, surgerywith
general anaesthesia; active cancer; APS;
antithrombin deficiency; serious liver or renal
disease; other indication/contraindication for
anticoagulation; limited life expectancy;
geographical inaccessibility)
Proximal leg DVT
or PE
Clinical visits every 3-6 months;
instructions to contact if have
symptoms
4/3
Shrivastava, 200625 Randomised
controlled,
multicentre
UnprovokedVTE (excluded: surgery or traumawithin
90 days of index event; APS; previous or active
cancer; life expectancy <3 years)
Leg DVT or PE Clinical visits every 2 months 3/3
Tait, 200735 Prospective cohort,
multicentre
Acute VTE in previous 5 weeks (excluded: life
expectancy <3 months; anticipated duration of
anticoagulation >1 year; unavailable for follow-up)
DVT or PE Nurse visit at 3 months, 1 year, and
2 years after stopping vitamin K
antagonist; instructions to contact if
have symptoms
Not applicable
Baglin, 200834 Prospective cohort,
single centre
First VTE (excluded: postoperative or pregnancy
associated VTE; APS; cancer; thrombosis within
6 weeks of surgery; other indication for prolonged
anticoagulation)
Proximal leg DVT
or PE
Yearly follow-up 3/3
Poli, 200833 Prospective cohort,
single centre
First unprovoked VTE or VTE due to reversible risk
factors (excluded: APS or active cancer)
Proximal leg DVT
or PE
Follow-up twice in first year and
annually thereafter; instructions to
contact if have symptoms
4/3
APS=antiphospholipid syndrome; DVT=deep vein thrombosis; PE=pulmonary embolism; VTE= venous thromboembolism.
*Based on Newcastle-Ottawa scale criteria for selection (4 criteria) and outcome (3 criteria); criteria assessing comparability were considered not relevant in frame of individual patient meta-
analysis.
RESEARCH
page 4 of 9 BMJ | ONLINE FIRST | bmj.com
Sensitivity analyses
Interaction between age, sex, and hormone associated initial
venous thromboembolism—The interaction between age
and sex suggested that age was a predictor in women
only (hazard ratio 1.02, 1.01 to 1.03), but adjustment
for hormonal therapy in a model with only women
almost completely explained the effect of age (hazard
ratio 1.01, 0.99 to 1.02).
Effect of hormone type (oral contraceptive, hormone repla-
cement therapy) in women with hormone associated initial
venous thromboembolism on risk of recurrence—Of 390
womenwith hormone associated initial venous throm-
boembolism, the type of hormonal therapy used was
specified in only 65 women (17%, 27 oral contracep-
tive users, 38 hormone replacement therapy users), so
we reclassified all women by using a threshold of the
value midway between the medians of age in women
on oral contraceptive or hormone replacement ther-
apy (47 years). Multivariable Cox modelling in only
women showed that compared with non-hormone
users who developed venous thromboembolism, oral
contraceptive associated initial venous thromboembo-
lism was associated with a lower risk of recurrence
(hazard ratio 0.39, 0.16 to 0.91); womenwith hormone
replacement therapy associated initial venous throm-
boembolism also had a lower risk of recurrence,
although this was not statistically significant (hazard
ratio 0.76, 0.39 to 1.49). These findings were indepen-
dent of the effect of age.
DISCUSSION
This analysis of more than 2500 patients with a first
venous thromboembolism who were followed, on
average, for 2.5 years after stopping anticoagulation
has three main findings. Firstly, among patients with
unprovoked venous thromboembolism men had a
2.2-fold higher risk of recurrence of disease than did
women. After adjustment for women with initial hor-
mone associated venous thromboembolism, a
potential major confounder, the risk of recurrence
remained 1.8-fold higher in men than in women. Sec-
ondly, in patients with provoked venous thromboem-
bolism the risk of recurrent disease did not differ
between men and women. Thirdly, in women with
hormone associated initial venous thromboembolism
the risk of recurrence was 50% lower than in women
without hormone associated initial venous throm-
boembolism.
Possible explanations of findings
Several hypotheses have been proposed to explain the
association between male sex and increased risk of
recurrent venous thromboembolism as one that is
spurious. Firstly, the increased risk of recurrence in
men is purportedly due to their more advanced age at
the time of diagnosis compared with women.11 In our
study, patient’s age was comparable in men and
women (mean age 58.8 v 57.6 years) and statistical
adjustment for age did not affect our findings. Sec-
ondly, sex specific differences in length of treatment
or post-treatment follow-up might account for differ-
ences in rates of recurrence of disease. In our study,
men received longer anticoagulation than did women
(mean 13.0 (SD11.0) v 9.0 (10.1)months), but the dura-
tion of anticoagulation does not seem to affect the risk
of recurrent venous thromboembolism.36 37 Men had a
comparable length of follow-up to women (mean 25.8
(SD 18.5) v 28.4 (20.5) months).
Thirdly, men might be more likely to have diagnos-
tic testing for recurrent venous thromboembolism than
women, as with coronary artery disease,38 and might
thus be more likely to be diagnosed as having a recur-
rence. Although we could not compare the threshold
for diagnostic testing for recurrent venous throm-
boembolism in men and women, no evidence exists
to suggest that such testing occurs less in women. Pre-
vious studies have found a higher prevalence of con-
firmed deep vein thrombosis in men than in women
Table 2 | Characteristics of patients
Author, year
No of
patients
No of men/
women
HT use
(yes/no/
unknown)
Mean (SD) age (years) Cause of
initial VTE
(provoked/
unpro-
voked)
Initial VTE
(PE or
proximal
DVT/distal
DVT)
Mean (SD)
duration of
anti-
coagulation
(months)
Mean (SD)
length of
follow-up
(months)
No (%) with
recurrent VTEAll men All women
Women on
HT
Palareti,
200331
529 267/262 40/489/0 62.6 (14.8) 64.0 (18.0) 37.9 (10.2) 221/308 491/38 7.1 (7.5) 18.0 (6.2) 43 (8.1)
Eichinger,
200332
567 254/313 164/403/0 52.5 (14.3) 46.7 (18.0) 37.8 (14.9) 0/567 434/133 8.5 (13.2) 37.7 (28.8) 77 (13.6)
Palareti,
200626
501 260/241 59/442/0 61.8 (14.3) 60.7 (17.4) 37.2 (11.0) 0/501 501/0 12.4 (11.0) 20.3 (8.3) 42 (8.4)
Shrivastava,
200625
149 75/74 46/27/76 54.8 (12.6) 52.3 (12.0) 51.2 (11.2) 1/148 131/18 8.3 (8.4) 24.5 (14.7) 15 (10.1)
Tait, 200735 250 136/114 32/218/0 58.1 (14.6) 57.9 (15.9) 46.1 (13.1) 119/131 250/0 6.0 (1.0) 20.6 (11.3) 27 (10.8)
Baglin,200834 271 142/129 19/252/0 60.5 (17.5) 65.3 (18.6) 43.6 (16.1) 74/197 271/0 6.3 (0.9) 37.7 (16.5) 49 (18.1)
Poli, 200833 287 152/135 30/256/1 58.6 (15.0) 60.3 (17.4) 43.9 (14.1) 110/177 287/0 13.3 (11.0) 31.7 (21.7) 37 (12.9)
Pooled 2554 1286/1268 390/2087/
77
58.8 (15.2) 57.6 (18.7) 40.7 (14.1) 525/2029 2365/189 8.9 (8.7) 27.1 (19.6) 290 (11.4)
DVT=deep vein thrombosis; HT=hormonal therapy; PE=pulmonary embolism; VTE=venous thromboembolism.
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with suspected thrombosis,39-41 suggesting that women
either are more likely to seekmedical attention for sus-
pected thrombosis or prompt a lower threshold for
diagnostic testing. Fourthly, men may have more
extensive venous thromboembolism than women,
whichmay lead to more recurrence.18 This is also unli-
kely, as the extent of disease seems to be similar inmen
and women.42 Fifthly, men might have a higher inci-
dence of occult cancer, which would lead to more
recurrent venous thromboembolism. Although our
included studies did not document the development
of cancer during follow-up and excluded patients
with cancer at the time of their initial venous throm-
boembolism, this explanation is unlikely as a differ-
ence in incidence of cancer in men and women with
venous thromboembolism has not been found.43-46
Sixthly, men may have a higher incidence of the
metabolic syndrome or other cardiovascular risk fac-
tors, which seem to confer an increased risk of venous
thromboembolism.47-49 If such factors are more com-
mon in men and contribute to the development of
recurrent venous thromboembolism, one would also
expect a higher incidence of first venous thromboem-
bolism in men, which has not been seen.1-3 Although
these associations are plausible, further study is
needed.50 51 Seventhly, men may be more likely to be
exposed to high risk situations, such as surgery, than
women and may develop more provoked recurrent
venous thromboembolism. However, a sex specific
predilection to risk factors for venous thromboembo-
lism, apart from use of hormonal therapy and preg-
nancy, seems unlikely. Although we were unable to
assess this in our database, a study assessing whether
men had more provoked recurrent venous throm-
boembolism events than women found that men had
more unprovoked recurrent events, which supports
our premise.52 Finally, the observed risk differential
in men and women may be due to a lower baseline
risk of recurrence inwomen. This is purportedly attrib-
uted to the fact that women develop hormone asso-
ciated initial venous thromboembolism, which
confers a lower risk of disease recurrence.53 Although
this explanation is plausible, it only partially accounts
for the sex specific difference in risk for recurrence.
In patients with provoked venous thromboembo-
lism, which occurred after exposure to a major risk
factor such as surgery, patient’s sex was not associated
with risk of recurrence. Although this finding may
seem to refute our conclusion of a sex specific effect
on recurrence, the interpretation of findings in this
subgroup of patients is limited because the number of
patients studied was smaller and patients with pro-
voked venous thromboembolism have a low risk of
recurrence.54 Furthermore, the confidence interval
around the risk estimate for recurrence in patients
with provoked venous thromboembolism did not
exclude a twofold higher risk in men than women.
The mechanism for sex specific recurrence may be
unique to patients with unprovoked venous throm-
boembolism. Also, women with hormone associated
initial venous thromboembolism have a 50% lower
risk of recurrence than do comparable women who
develop venous thromboembolism in the absence of
any antecedent risks. This suggests that hormone asso-
ciated initial venous thromboembolism, particularly
for oral contraceptive associated disease, has a clinical
course that is more comparable to that of provoked
venous thromboembolism than unprovoked disease.
In another study assessing risk of recurrence after hor-
mone associated initial venous thromboembolism,
although the risk of recurrence did not seem to be
lower in women with oral contraceptive associated
venous thromboembolism (hazard ratio 0.6, 95% con-
fidence interval 0.1 to 2.8) or hormone replacement
therapy associated disease (1.8, 0.6 to 5.2) who stopped
hormonal therapy, the findings should be interpreted
with caution because of wide confidence limits around
the risk estimates.55
Strengths and limitations of study
The strength of our study is that it represents, to our
knowledge, the largest prospectively derived data
source comparing the risk of recurrent venous throm-
boembolism in men and women. When juxtaposed
against a study level meta-analysis of 5416 patients in
which recurrent venous thromboembolism was com-
pared in men and women,11 the findings for risk of
recurrence after unprovoked venous thromboembo-
lism were similar in this study (relative risk 1.5, 1.1 to
1.9) andour study (1.8, 1.4 to 2.5).However, in patients
withprovokedvenous thromboembolism,whereas the
study level meta-analysis reported a higher risk of
recurrence in men than in women (relative risk 1.5,
1.1 to 2.1), our findings differed (1.2, 0.6 to 2.4). Such
comparisons, however, need cautious interpretation
given differences in analytical methods. In individual
studies assessing patients with treated venous throm-
boembolism, the risk of recurrent disease was higher
in men than in women in most,5 6 56-62 but not all,8 63
studies.
Table 3 | Cumulative incidence of recurrent venous thromboembolism (VTE) in all patients according to sex and hormonal therapy status
Time after anticoagulation
stopped
Cumulative incidence of recurrent VTE: events per patient year of follow-up (95% CI)
All men All women
Men with
unprovoked VTE
Women with unprovoked VTE (including
women with previous hormone
associated VTE)
Women with unprovoked VTE (excluding
women with previous hormone
associated VTE)
1 year 9.5 (7.9 to 11.4) 5.3 (4.1 to 6.7) 10.4 (8.6 to 12.8) 5.6 (4.3 to 7.3) 6.7 (4.9 to 9.2)
2 years 14.1 (11.9 to 16.6) 7.9 (6.4 to 9.8) 15.8 (13.2 to 18.8) 8.3 (6.6 to 10.5) 10.6 (8.1 to 13.8)
3 years 19.7 (16.5 to 23.4) 9.1 (7.3 to 11.3) 22.5 (18.8 to 27.0) 9.1 (7.2 to 11.6) 10.6 (8.1 to 13.8)
5 years 36.3 (28.7 to 45.9) 11.1 (8.6 to 14.4) 43.1 (33.8 to 55.1) 11.5 (8.7 to 15.2) 12.2 (9.3 to 16.2)
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We acknowledge potential limitations. Firstly, our
findings are limited to the studies included in this
meta-analysis. Although this may imply a study selec-
tion bias, we pre-specified the study selection criteria,
thus minimising such bias. The advantage gained with
a patient level meta-analysis was in having a large sam-
ple of original data and the ability to adjust for potential
confounders.11 Secondly, unmeasured determinants
may explain the differential risk of recurrence of
venous thromboembolism in men and women, and
additional research is needed to explain our findings.
Thirdly, including patients with hormonal therapy
associated initial venous thromboembolism as unpro-
voked disease may be questioned. We made this deci-
sion a priori, and the fact that hormonal therapy is
considered to be a weak risk factor for venous throm-
boembolism compared with major risk factors such as
surgery justifies this.16 Furthermore, a standard defini-
tion of unprovoked venous thromboembolism is lack-
ing; some studies have included hormone associated
venous thromboembolism as unprovoked,4 26 63 64
whereas others have not.36 65 None the less, we pre-
specified analyses that would adjust for these sub-
groups of patients when assessing risk of recurrence
in men and women. Finally, our findings are based
on a predominantly white population and may not be
applicable to other racial groups, in whom further
research is needed to assess prognosis of venous
thromboembolism.66
Implications of findings
Our findings suggest that in patients with a first unpro-
voked venous thromboembolism, patient’s sexmaybe
an important consideration in deciding about the need
for long term anticoagulant treatment. Ideally, a
clinical prediction guide that incorporates objective
clinical, imaging (residual thrombosis on venous ultra-
sonography), and laboratory (post-anticoagulation
D-dimer) factors to predict recurrence should be
sought.67 One clinical prediction rule seemed to be use-
ful in women but not men with unprovoked venous
thromboembolism.5 Additional studies to look at this
are planned.68 Our finding that women with hormone
associated venous thromboembolism have a lower risk
of recurrence than dowomenwith venous thromboem-
bolism that occurs in the absenceof any antecedent risks
may reassure clinicians andpatients of a goodprognosis
after hormone associated disease, assuming disconti-
nuation of hormonal therapy. Overall, our findings are
relevant to the considerable number of patients world-
wide, estimated to be 200 000 in North America alone,
who are diagnosed each year as having a first episode of
venous thromboembolism.36970
Conclusions
In patients with a first unprovoked venous throm-
boembolism, men have a 2.2-fold higher risk of recur-
rent venous thromboembolism than do women. This
risk remained 1.8-fold higher inmen thanwomen after
adjustment for women who had hormone associated
venous thromboembolism. In patients with a first pro-
voked venous thromboembolism, we found no differ-
ence in risk of recurrence between men and women.
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Table 4 | Predictors of recurrent venous thromboembolism (VTE) in multivariable Cox
regression analysis
Groups of patients for comparison
Risk of recurrent VTE—
hazard ratio (95% CI)*
Initial VTE unprovoked†:
Men v all women‡ 2.2 (1.7 to 2.8)
Men v women (excluding women with previous hormone associated VTE)§ 1.8 (1.4 to 2.5)
Women with previous hormone associated VTE v women without previous
hormone associated VTE and no other antecedent risk factors
0.5 (0.3 to 0.8)
Initial VTE provoked¶:
Men v all women‡ 1.2 (0.6 to 2.4)
Men v women (excluding women with previous hormone associated VTE)§ 1.2 (0.6 to 2.3)
*All estimates came from study stratified Cox regression model with fixed effect (as no significant variance of γ
distribution for “shared frailty” was seen).
†VTE occurring in absence of major antecedent risk (for example, surgery, trauma).
‡Hazard ratio from model including age, unprovoked/provoked VTE, interaction between unprovoked/provoked
and sex, and proximal/distal VTE as covariates.
§Hazard ratio from model including use/non-use of hormonal therapy, age, unprovoked/provoked VTE,
interaction between unprovoked/provoked VTE and sex, and proximal/distal VTE as covariates.
¶VTE occurring in presence of antecedent transient major risk.
WHAT IS ALREADY KNOWN ON THIS TOPIC
Whether men have a higher risk of recurrent venous thromboembolism than do women is
uncertain, partly because previous studies did not control for potential sources of bias
If men are at higher risk of recurrence, this would mean that men may need a longer duration
of anticoagulant treatment than do women
WHAT THIS STUDY ADDS
After unprovoked venous thromboembolism, the risk of recurrence is 2.2-fold higher in men
than in women; this remained 1.8-fold higher after adjustment for women who had hormone
associated disease
After provoked venous thromboembolism, the risk of recurrence is similar in men and women
Indefinite anticoagulation may be given greater consideration in men than in women after a
first venous thromboembolism
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